RPG Life Sciences Ltd
Company Profile
Business description
RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The company is exclusively engaged in the pharmaceutical business and operates across Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients (API). It offers a range of high-value synthetic APIs in the general therapeutic category, with a growing product portfolio covering immunosuppressants, antipsychotics, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, and other therapeutic categories. The company has a presence in Europe, Latin America, and Asia, and is making forays into the US markets. It has one reportable business segment, Pharmaceuticals.
Contact
463, Dr. Annie Besant Road
RPG House
Worli
MumbaiMH400030
INDT: +91 2269757100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
1,288
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 32.70 | -0.36% |
| CAC 40 | 8,372.28 | 0.00 | 0.00% |
| DAX 40 | 25,099.00 | 335.88 | 1.36% |
| Dow JONES (US) | 51,947.25 | 235.60 | 0.46% |
| FTSE 100 | 10,736.23 | 97.06 | 0.91% |
| HKSE | 24,963.23 | 247.58 | -0.98% |
| NASDAQ | 24,975.82 | 161.87 | -0.64% |
| Nikkei 225 | 64,611.15 | 1,811.45 | -2.73% |
| NZX 50 Index | 13,772.29 | 23.02 | -0.17% |
| S&P 500 | 7,411.98 | 3.68 | 0.05% |
| S&P/ASX 200 | 8,772.30 | 23.40 | -0.27% |
| SSE Composite Index | 3,814.20 | 62.58 | -1.61% |